Lv51
840 积分 2021-03-06 加入
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial
3天前
已完结
CAR-T triggers TAM reeducation and adaptive anti-tumor response via TREM2 deficiency or CD40 agonist
6天前
已关闭
Revisiting Prophylactic Corticosteroids to Mitigate Severe Immune-Related Adverse Events in Hepatocellular Carcinoma
6天前
已完结
Establishment of a clinical model based on vessels encapsulating tumour clusters that could efficiently predict recurrence of patients with hepatocellular carcinoma after curative hepatectomy
14天前
已完结
Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular HCC
14天前
已完结
Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
1个月前
已完结
SMAD4 May Serve as a Candidate Molecular Marker for Immune-Based Therapies Across Human Pan-Cancer
1个月前
已完结
Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study
1个月前
已完结
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
1个月前
已完结
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
2个月前
已完结
皖公网安备34019202002308
